CA
RVMD icon

Continuum Advisory’s Revolution Medicines RVMD Stock Holding History

Continuum Advisory’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18K Buy
+17
New +$2.48K ﹤0.01% 1605
2025
Q1 		– Sell
-74
Closed -$3.24K – 1886
2024
Q4 		$3.24K Buy
74
+1
+1% +$50 ﹤0.01% 1258
2024
Q3 		$4.19K Buy
73
+59
+421% +$2.57K ﹤0.01% 1207
2024
Q2 		$543 Hold
14
– – ﹤0.01% 1583
2024
Q1 		$524 Buy
+14
New +$415 ﹤0.01% 1596

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Continuum Advisory's RVMD Position: Q2 2026 in Review

Continuum Advisory opened a new position in Revolution Medicines (RVMD) in Q2 2026: 17 shares worth $3.18K. The stake represents ﹤0.01% of the portfolio and ranks #1605 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in RVMD as recently as Q4 2024.

Continuum Advisory first reported a position in RVMD in Q1 2024 and has held it in 5 quarters since. The position peaked at $4.19K in Q3 2024. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Continuum Advisory held 17 shares of Revolution Medicines worth $3.18K as of Q2 2026.
  • Revolution Medicines was a new Continuum Advisory position in Q2 2026.
  • Revolution Medicines made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1605 holding.
  • Continuum Advisory first reported a position in Revolution Medicines in Q1 2024 and has held it in 5 quarters since.
  • Continuum Advisory's Revolution Medicines position peaked at $4.19K in Q3 2024.
  • 693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.